PURPOSE: Microsatellite instable-high (MSI-H) colorectal cancers (CRCs) are known to carry better survival in the local disease stage even without treatment. The influence of types of treatment on survival of MSI-H metastatic CRCs (mCRCs) is still unclear and is evaluated in this study. MATERIALS AND METHODS: Patients with MSI-H mCRC treated with first-line chemotherapy, with or without bevacizumab, identified in the Israeli population-based Molecular Epidemiology of Colorectal Cancer (MECC) study, were diagnosed between 1998 and 2013 and followed up until May 2017; MSI status was determined by comparing 10 markers in tumor and normal tissue. Dates of metastases and death and treatment details were extracted from oncology records. RESULTS: Among 590 patients treated for mCRC, 106 (18%) had MSI-H tumors. Patients with MSI-H had a median overall survival (OS, from start of first-line treatment) of 1.6 years. The presence of a somatic B-Raf proto-oncogene (BRAF) mutation was a significant adverse prognostic factor in the MSI-H group (hazard ratio [HR], 1.8; 95% CI, 1.1 to 3.0; P = .026). MSI-H tumors without BRAF mutation (n = 87) had similar OS benefit from fluorouracil (FU) only as from any combination protocols (HR, 0.93; P = .78), whereas microsatellite-stable (MSS) tumors without BRAF mutation (n = 456) showed improved OS over FU-only regimens when combination chemotherapy with or without bevacizumab was used (HR, 0.58; P < .01; P value for interaction = .07). Patients with MSI-H/BRAF wild type (WT) had survival advantage over patients with MSS disease (adjusted HR, 0.58; 95% CI, 0.35 to 0.98) when treated with FU-only protocols. CONCLUSION: Clinical outcomes differ substantially between patients with MSS/BRAF-WT mCRC and MSI-H/BRAF-WT mCRC, with measurable differences between chemotherapy regimens. MSI-H mCRCs are a clinically distinct subset of colorectal cancers. Their current poor outcome suggests that new clinical trials are needed to identify therapeutic options, potentially taking advantage of the new developments in the field of immunotherapy.
PURPOSE: Microsatellite instable-high (MSI-H) colorectal cancers (CRCs) are known to carry better survival in the local disease stage even without treatment. The influence of types of treatment on survival of MSI-H metastatic CRCs (mCRCs) is still unclear and is evaluated in this study. MATERIALS AND METHODS: Patients with MSI-H mCRC treated with first-line chemotherapy, with or without bevacizumab, identified in the Israeli population-based Molecular Epidemiology of Colorectal Cancer (MECC) study, were diagnosed between 1998 and 2013 and followed up until May 2017; MSI status was determined by comparing 10 markers in tumor and normal tissue. Dates of metastases and death and treatment details were extracted from oncology records. RESULTS: Among 590 patients treated for mCRC, 106 (18%) had MSI-H tumors. Patients with MSI-H had a median overall survival (OS, from start of first-line treatment) of 1.6 years. The presence of a somatic B-Raf proto-oncogene (BRAF) mutation was a significant adverse prognostic factor in the MSI-H group (hazard ratio [HR], 1.8; 95% CI, 1.1 to 3.0; P = .026). MSI-H tumors without BRAF mutation (n = 87) had similar OS benefit from fluorouracil (FU) only as from any combination protocols (HR, 0.93; P = .78), whereas microsatellite-stable (MSS) tumors without BRAF mutation (n = 456) showed improved OS over FU-only regimens when combination chemotherapy with or without bevacizumab was used (HR, 0.58; P < .01; P value for interaction = .07). Patients with MSI-H/BRAF wild type (WT) had survival advantage over patients with MSS disease (adjusted HR, 0.58; 95% CI, 0.35 to 0.98) when treated with FU-only protocols. CONCLUSION: Clinical outcomes differ substantially between patients with MSS/BRAF-WT mCRC and MSI-H/BRAF-WT mCRC, with measurable differences between chemotherapy regimens. MSI-H mCRCs are a clinically distinct subset of colorectal cancers. Their current poor outcome suggests that new clinical trials are needed to identify therapeutic options, potentially taking advantage of the new developments in the field of immunotherapy.
Authors: Laura S Rozek; Stephanie L Schmit; Joel K Greenson; Lynn P Tomsho; Hedy S Rennert; Gad Rennert; Stephen B Gruber Journal: J Natl Cancer Inst Date: 2016-05-12 Impact factor: 13.506
Authors: Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello Journal: J Clin Oncol Date: 2011-04-18 Impact factor: 44.544
Authors: W M Brueckl; C Moesch; T Brabletz; C Koebnick; C Riedel; A Jung; S Merkel; S Schaber; F Boxberger; T Kirchner; W Hohenberger; E G Hahn; A Wein Journal: Anticancer Res Date: 2003 Mar-Apr Impact factor: 2.480
Authors: Shyam M Kavuri; Naveen Jain; Francesco Galimi; Francesca Cottino; Simonetta M Leto; Giorgia Migliardi; Adam C Searleman; Wei Shen; John Monsey; Livio Trusolino; Samuel A Jacobs; Andrea Bertotti; Ron Bose Journal: Cancer Discov Date: 2015-08 Impact factor: 39.397
Authors: David L Chan; Nick Pavlakis; Jeremy Shapiro; Timothy J Price; Christos S Karapetis; Niall C Tebbutt; Eva Segelov Journal: PLoS One Date: 2015-08-14 Impact factor: 3.240
Authors: J C von Einem; V Heinemann; L Fischer von Weikersthal; U Vehling-Kaiser; M Stauch; H G Hass; T Decker; S Klein; S Held; A Jung; T Kirchner; M Haas; J Holch; M Michl; P Aubele; S Boeck; C Schulz; C Giessen; S Stintzing; D P Modest Journal: J Cancer Res Clin Oncol Date: 2014-05-10 Impact factor: 4.553
Authors: Hossein Taghizadeh; Robert M Mader; Leonhard Müllauer; Friedrich Erhart; Alexandra Kautzky-Willer; Gerald W Prager Journal: J Pers Med Date: 2020-12-11
Authors: A Echle; N Ghaffari Laleh; P Quirke; H I Grabsch; H S Muti; O L Saldanha; S F Brockmoeller; P A van den Brandt; G G A Hutchins; S D Richman; K Horisberger; C Galata; M P Ebert; M Eckardt; M Boutros; D Horst; C Reissfelder; E Alwers; T J Brinker; R Langer; J C A Jenniskens; K Offermans; W Mueller; R Gray; S B Gruber; J K Greenson; G Rennert; J D Bonner; D Schmolze; J Chang-Claude; H Brenner; C Trautwein; P Boor; D Jaeger; N T Gaisa; M Hoffmeister; N P West; J N Kather Journal: ESMO Open Date: 2022-03-02